The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

Key facts

Sponsor

Yale University

Principal Investigator

Pasquale Patrizio, MD, MBE, HCLD

Yale University

Intervention

Human Albumin Infusion(drug)

Eligibility

18-42 years · FEMALE

Timeline

2007

Study locations (1)

• Yale Fertility Center, New Haven, Connecticut, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Ovarian hyperstimulation syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07043322
  Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome
  Tanta University

See all trials for Ovarian hyperstimulation syndrome →